HUTCHMED (NASDAQ:HCM) Stock Rating Upgraded by StockNews.com

HUTCHMED (NASDAQ:HCM) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Friday.

HUTCHMED Price Performance

HCM opened at $14.99 on Friday. HUTCHMED has a 1-year low of $12.84 and a 1-year high of $21.92. The business has a 50 day moving average of $14.69 and a 200-day moving average of $16.50. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HCM. Jane Street Group LLC grew its position in HUTCHMED by 362.2% during the third quarter. Jane Street Group LLC now owns 62,997 shares of the company’s stock worth $1,305,000 after buying an additional 49,366 shares in the last quarter. XY Capital Ltd acquired a new stake in shares of HUTCHMED during the 4th quarter worth approximately $673,000. ABC Arbitrage SA bought a new stake in shares of HUTCHMED during the fourth quarter valued at approximately $500,000. Renaissance Technologies LLC raised its stake in shares of HUTCHMED by 18.4% in the fourth quarter. Renaissance Technologies LLC now owns 188,539 shares of the company’s stock valued at $2,717,000 after purchasing an additional 29,239 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its position in HUTCHMED by 99.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company’s stock worth $952,000 after purchasing an additional 24,245 shares during the period. Institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.